ERS Genomics and IRBM Sign CRISPR/Cas9 License Agreement
20 May 2024 //
BUSINESSWIRE
IRBM to Disclose Strong Antitumor Efficacy of Novel Preclinical Agents at AACR
04 Apr 2024 //
PR NEWSWIRE
IRBM Extends Peptide Therapeutics Collaboration with Merck & Co
22 Jun 2023 //
GLOBENEWSWIRE
IRBM Selected for Participation in National Chemical Biology Consortium
04 Apr 2023 //
GLOBENEWSWIRE